ADVERTISEMENT
Value-Added Medicines
Generics Bulletin previews the most noteworthy and anticipated events for February 2026.
Hyloris and Orion continue to build on their partnership with another value-added medicine collaboration in Europe.
European CNS specialist rolls out a value-added methylphenidate and a first-to-market guanfacine generic as it sharpens its European ADHD strategy.
Management says it is prepared to sacrifice early volume if pricing fails to reflect the drug’s role in moderate to severe schizophrenia.
Management says it is prepared to sacrifice early volume if pricing fails to reflect the drug’s role in moderate to severe schizophrenia.
Amphastar is looking to a “strategically important addition to our growing proprietary peptide portfolio,” after striking an exclusive licensing agreement with China-based Nanjing Hanxin Pharmaceutical Technology.
Latest agreement with Rosemont underscores Hyloris’ value-added medicines strategy and asset-light US partnering.
Viatris is entering the new year with several key achievements under its belt.
Generics Bulletin previews the most noteworthy and anticipated events for January 2026.
A pair of private equity mega-deals dominated the mergers and acquisitions landscape in 2025, but there was still a clear appetite for smaller, strategic takeovers and tuck-ins across the generics, biosimilars, and off-patent medicines field.
The launch of Tyzavan, a ready-to-use vancomycin premix, comes amid plans to accelerate growth for Hikma’s injectables portfolio and strengthen its European and US market presence.
Teva sees olanzapine LAI as key to building a schizophrenia franchise worth up to $2bn annually, following its earlier risperidone launch.